Andreessen Horowitz led a $100m Series A round in Dyno Therapeutics, a biotechnology company applying artificial intelligence to gene therapy, with participation from Casdin Capital, GV, Obvious Ventures, Lux Capital, Polaris Partners, CRV and KdT Ventures. "This Series A financing accelerates our AI-powered discovery of best-in-class capsids targeting all major organs and cell types, enabling Dyno to grow our business infrastructure and establish more partnerships to become the premier developer of gene therapy vectors," Eric Kelsic, Dyno Therapeutics Founder and CEO.